Clinical Trials Logo

Clinical Trial Summary

A Phase III trial to demonstrate the safety and efficacy of PTK 0796 in the treatment of complicated skin and skin structure infections (cSSSI).


Clinical Trial Description

The pharmacologic profile of PTK 0796 in humans suggests that it has the potential to be used safely and effectively for this indication. Data from in vitro and animal studies support this hypothesis.

In PTK 0796-CSSI-0805 the safety and efficacy of PTK 0796 in the treatment of cSSSI will be compared to an antibiotic approved for this indication by the FDA. Initial treatment will be administered intravenously with the option for subsequent oral treatment. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00876850
Study type Interventional
Source Paratek Pharmaceuticals Inc
Contact
Status Withdrawn
Phase Phase 3
Start date July 2009
Completion date August 2010

See also
  Status Clinical Trial Phase
Completed NCT02607618 - Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2 Phase 3
Completed NCT02600611 - Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1 Phase 3
Completed NCT01984684 - Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections Phase 3
Completed NCT02378480 - Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23) Phase 3
Completed NCT02863874 - The PLUS Study: Comparison of VicrylPlus® Versus Vicryl® for Repair of Perineal Tears N/A
Completed NCT02877927 - Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI Phase 3